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Para-aortic lymph node (PALN) metastasis is an important prognostic factor in patients with 
pancreatic cancer, but accurate preoperative diagnosis is difficult.  The aim of this study was to 
assess the accuracy of diagnosing PALN by computed tomography (CT), magnetic resonance 
imaging (MRI), and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). 
 
Methods 
From August 2005 to July 2008, 119 patients with invasive ductal adenocarcinoma of the pancreas 
were included in this study.  PALNs with a longer diameter >10 mm on CT or MRI were suspected 
to be involved by metastasis, while 18F-fluorodeoxyglucose (FDG) uptake exceeding that of the 
adjacent normal tissue was considered to be positive for metastasis on FDG-PET studies.  The 
imaging findings were compared with the pathological diagnosis of PALN metastasis. 
 
Results 
PALN dissection was performed in 71 patients (60.0%).  Although histopathological examination 
revealed metastasis in 6 patients (8.5%), none of these patients were positive in any of the 
preoperative imaging studies.  The longer diameter, the shorter diameter, the ratio of the two 
diameters, and the calculated lymph node volume showed no significant differences between 
patients with and without PALN metastasis. 
 
Conclusions 
Preoperative detection of PALN metastasis in patients with pancreatic cancer is very difficult.  









Para-aortic lymph node metastasis is an important prognostic factor in patients with pancreatic 
cancer, but accurate preoperative diagnosis is difficult. Intraoperative histopathological examination 




Even in the 21st century, pancreatic cancer still has a dismal prognosis.  The overall median 
survival time is 8.6 months and 5-year survival rate is 9.7% for Japanese patients with invasive 
ductal adenocarcinoma 1.  Complete surgical resection is the only potentially curative treatment 
available, but less than 20% of all patients have resectable disease and the 5-year overall survival of 
resectable patients is still only 10-20% 2.  Although extended radical surgery has been performed 
for various stages of pancreatic cancer, extended lymphadenectomy has not been shown to prolong 
survival compared with standard lymphadenectomy 1, 3.  The presence of PALN metastasis is 
reported to be an important adverse prognostic factor in patients with pancreatic cancer 4.  
Therefore, preoperative evaluation of the PALN status is one of the most important factors when 
deciding whether pancreatic resection should be performed or not. 
It was reported that only 33% of PALN metastases are suspected preoperatively or 
perioperatively 5.  The ability of preoperative imaging modalities to evaluate local resectability 
and to identify metastatic disease has increased substantially, and helical computed tomography 
(CT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), endoscopic 
retrograde cholangiopancreaticography (ERCP), and 18F-fluorodeoxyglucose positron emission 
tomography (FDG-PET) are commonly used at present.  Among these modalities, CT and EUS are 
considered to be the most useful with respect to staging of pancreatic cancer 6, 7.  However, the 
detection of small liver metastases and peritoneal metastases remains limited 8.  Similarly, the 
sensitivity of these imaging methods for lymph node metastasis is low (EUS, 67%; CT, 55%; MRI, 
75%), and lymph node metastasis of pancreatic cancer remains difficult to detect preoperatively 7. 
At our hospital, PALN dissection precedes other procedures in patients with pancreatic cancer 
because we do not perform radical pancreatectomy if PALN metastasis is detected by intraoperative 
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frozen section diagnosis.  Therefore, if we could determine the presence of PALN metastasis 
before laparotomy, this would be beneficial for our patients. 
Accordingly, the purpose of the present study was to examine the diagnostic accuracy of 
preoperative imaging modalities (CT, MRI, and FDG-PET) for PALN metastasis in patients with 
invasive carcinoma of the pancreas.  Based on our findings, it remains very difficult to detect 





Patients from our hospital in whom a histopathological diagnosis of invasive ductal 
adenocarcinoma of the pancreas was made between August 2005 and July 2008 were included in 
this study.  Patients with other pancreatic malignancies, such as intraductal papillary mucinous 
neoplasms or neuroendocrine tumors, were excluded. 
Patients routinely underwent preoperative contrast-enhanced helical CT, MRI, and FDG-PET to 
assess the resectablity and stage of the tumor according to the Classification of Pancreatic 
Carcinoma by the Japan Pancreas Society (JPS) 9 and the TNM classification of the Union 
International Contra la Cancrum (UICC) 10. 
 
Surgical procedure 
If the tumor was considered to be resectable as a result of preoperative assessment, the patient 
underwent laparotomy. Resectable disease was defined as the absence of distant metastasis and no 
infiltration of major arteries, such as the common hepatic, celiac, and superior mesenteric arteries.  
Invasion of the portal vein (PV), superior mesenteric vein (SMV), or splenic vein was not a 
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contraindication to resection, and such vessels were resected if necessary. 
At the start of surgery, 50 ml of warm saline was infused into the Pouch of Douglas and was 
collected for intraoperative cytological examination.  Liver metastasis and peritoneal 
dissemination were assessed by inspection and palpation.  If metastasis or dissemination was 
suspected, the lesions were investigated by intraoperative frozen section examination.  Next, 
dissection of the PALNs between the celiac axis and the inferior mesenteric artery was performed. 
This involved total resection of the lymph nodes belonging to stations 16a2 and 16b1 11. These 
lymph nodes were also submitted for intraoperative frozen section examination. 
If tumor cells were found by cytological examination, or if liver metastasis, peritoneal 
dissemination, or PALN metastasis was detected, radical resection was abandoned and we selected 
palliative surgery plus postoperative systemic chemotherapy. Otherwise, pancreaticoduodenectomy 
(with or without pylorus preservation), distal pancreatectomy, or total pancreatectomy was 
performed according to the tumor location. 
Postoperatively, the formalin-fixed resected specimens with attached lymph nodes were 
examined histopathologically for definitive tumor staging.  Intraoperative samples were also 
examined again after formalin fixation. 
 
Preoperative CT, MRI and FDG-PET 
CT scanning was performed with a 64-detector row scanner (Aquilion Toshiba Medical, Tokyo, 
Japan) at a tube voltage of 120 kV, 200-250 mAs per 360 degrees, gantry rotation time of 0.5 
seconds, detector collimation of 64 x 0.5 mm, and table feed of 26.5 mm per rotation.  Contrast 
medium (Iopamiron: Bayer-Schering Pharma, Germany; Iomeron: Bracco-Eisai, Tokyo, Japan) was 
injected intravenously over 30 seconds at a dose of 2 ml/kg using a power injector (Auto Enhance 
A-50; Nemoto Kyorindou, Tokyo, Japan).  In all cases, RealPrep was used to determine the timing 
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of scans and the threshold was set at 200 HU attenuation in the lower descending aorta.  The 
scanning delay for the late arterial and equilibrium phases was 25 and 60 seconds, respectively. 
MRI was performed with a 1.5 T super conducting MR unit (Magnetom Symphony, Siemens, 
Germany).  Three types of images (breath-holding T1-weighted gradient-echo images in the axial 
plane [GE, slice thickness, 6 mm; slice gap, 1 mm], breath-holding true FISP images in the coronal 
plane [slice thickness, 5 mm; slice gap, 0 mm], and respiration-triggered T2-weighted turbo 
spin-echo images in the axial plane [slice thickness, 6 mm; slice gap, 1 mm]) were obtained. 
FDG-PET was performed by using a high-resolution, whole-body PET scanner with an 18-ring 
detector (Advance; General Electric Medical Systems, Milwaukee, WI).  All patients received an 
intravenous injection of 18F-FDG (296 ± 74 MBq) at 50 minutes before the acquisition of 
whole-body PET images was started.  Emission images were acquired for 3 minutes per bed 
position, and each post-emission transmission scan was acquired for 1 minute per position.  
Whole-body scanning (from the face to upper thighs) was performed in each patient by using five or 
six bed positions according to their height.  Data were reconstructed by the ordered subsets 
expectation maximization method (OSEM) using 16 subsets, 3 iterations, and a 128 x 128 array. 
 
Image analysis 
All images were interpreted by at least two experienced radiologists who used all available 
clinical information and had correlative conventional imaging for anatomic guidance (Figure 1). 
On CT and MRI, the shorter and longer diameters of the largest PALN were measured in both 
axial and coronal images. PALNs with a longer diameter > 10 mm were suspected to be involved by 
metastasis.  The estimated PALN volume was calculated as 0.5 x L x S2 [L: longer diameter, S: 
shorter diameter]. 
On PET images, regions of interest (ROIs) were manually defined on transaxial tomograms for 
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semiquantitative analysis of 18F-FDG uptake and experienced nuclear medicine physicians read the 
PET images.  When a PALN showed increased 18F-FDG accumulation compared with the 
surrounding tissues that was not related to normal physiologic uptake, it was considered to be 
positive for malignancy. Sites of increased 18F-FDG uptake were not considered to indicate 




Results are expressed as the mean ± SD.  Differences between two groups were analyzed by 
using the χ2 test.  Statistical analysis was performed with JMP software (SAS institute, Cary, NC) 







This study included 119 patients with a histological diagnosis of invasive ductal carcinoma of 
the pancreas from August 2005 to July 2008.  Their clinical, surgical, and histopathological 
findings are presented in Tables 1 and 2. 
Curative resection was performed in 85 patients (71.4%) and palliative surgery, including 
duodenal and/or biliary bypass, was done in 17 patients (14.3%).  Surgical intervention was not 
performed in the remaining 17 patients (14.3%).  Pancreatoduodenectomy was performed in 54 
patients, as well as total pancreatectomy in 8 patients and resection of the distal pancreas in 23 
patients. 
Combined resection of the PV or SMV was done in 26 patients, and tumor invasion of the 
vessel was histologically confirmed in 10 patients.  Over 90% of the tumors were T3 or T4 
according to both the JPS and UICC classifications. Sixty-six patients (55.5%) had lymph node 
metastasis and 32 patients (26.9%) had distant metastasis. 
PALN dissection was performed in 71 patients (60.0%), while it was not performed in the 
remaining 48 patients (40.0%) because of liver metastasis, peritoneal dissemination, or malignant 
cells on abdominal lavage cytology.  PALN metastasis was confirmed histologically in 6 patients 
(8.5%), and lymph node metastasis was detected by intraoperative frozen section examination in 5 
of them.  In one patient, intraoperative examination failed to detect lymph node metastasis, but it 
was revealed by postoperative examination of formalin-fixed sections. 
A comparison of clinical characteristics and tumor stage between the patients with and without 
PALN metastasis is presented in Table 3.  It can be seen that the age, gender, tumor location, tumor 
size, and T factor of the patients with PALN metastasis were similar to those of the patients without 
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metastasis.  However, the N factor, M factor, and tumor stage (according to both the JPS and 
UICC classifications) differed between the two groups because the patients with PALN metastasis 
were classified as M1 and stage IV according to JPS. 
 
Diagnostic accuracy of preoperative imaging 
Assessment of the diagnostic accuracy of preoperative imaging studies was presented in Table 4.  
According to preoperative CT, 13 patients were suspected to have PALN metastasis, but metastasis 
was not found by histological examination in any of these patients.  Similarly, 2 patients were 
suspected to have PALN metastasis on preoperative MRI and one patient by PET, but metastasis 
was not found in any of them on histological examination. 
Finally, 6 patients were histologically diagnosed as having PALN metastasis, but these 
metastases were not found by any of the preoperative imaging studies (a sensitivity of 0% for each 
modality).  In contrast to the low sensitivity, the specificity and accuracy were relatively high, 
being 79.4% and 72.5% for CT，96.8% and 88.4% for MRI，and 98.4% and 90.0% for FDG-PET, 
respectively. 
A comparison of lymph node size between patients with and without PALN metastasis is 
presented in Table 5.  The longer diameter, shorter diameter, and ratio of the longer to shorter 
diameters of the PALN on imaging studies did not differ significantly between the two groups.  
The calculated volume of PALN with metastases was slightly larger than that of PALN without 





Lymph node metastasis is one of the most important prognostic factors for gastrointestinal 
cancer, including pancreatic cancer.  The PALNs are considered to be the final nodes that are 
invaded by periampullary and gastric cancers before the tumor enters the systemic lymphatic 
circulation.  Accordingly, the majority of surgeons believe that metastases to these nodes represent 
systemic disease and they recommend that radical surgery (including extended lymphadenectomy) 
should not be done in patients with PALN metastasis 4, 12, 13.  Therefore, whether or not PALN 
metastasis exists is a major determinant of the surgical strategy. 
Patients with PALN metastasis frequently also have distant metastases, such as liver 
involvement or peritoneal dissemination. If such distant metastases are not found, PALN metastasis 
is the final decider of whether or not a patient has resectable disease. The actual sensitivity of CT, 
MRI, and FDG-PET for diagnosis of PALN metastasis in patients with pancreatic cancer might be 
higher than that shown by the present study, because a large number of patients who were obviously 
not suitable for surgical resection due to distant metastasis were not included in this investigation.  
However, the fact that preoperative imaging studies could not detect histological PALN metastasis 
in any of our 6 patients should be emphasized, because it indicates that intraoperative frozen section 
examination is required to determine the treatment strategy for patients with pancreatic cancer even 
if preoperative imaging does not suggest PALN metastasis. 
It remains controversial how to distinguish metastatic lymph nodes from normal lymph nodes 
on imaging studies.  Lymph node size is most frequently used, but there is no precise criterion to 
differentiate benign from metastatic nodes. For example, the longer diameter, shorter diameter, or 
longer/shorter diameter ratio are frequently used parameters, but the reference values used differ 
between each report 14, 15.  In patients with pancreatic cancer, imaging modalities show poor 
performance for detecting lymph node metastases and previous studies have shown that it is very 
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hard to assess nodal involvement simply from the size or to determine the appropriate criterion 7, 16, 
17.  Therefore, CT and MRI have a low priority with respect to identification of metastatic lymph 
nodes. 
Previously, we reported that FDG-PET is not only useful for differentiating between pancreatic 
cancer and chronic pancreatitis but also for detecting small early pancreatic tumors 18. It has been 
reported that the sensitivity of FDG-PET is 85% to 100% and the specificity is 53% to 100% for the 
diagnosis of pancreatic carcinoma 18-22.  However, the ability of FDG-PET to detect small 
metastases is quite limited and this imaging modality has not been found to significantly increase 
the accuracy of diagnosing metastasis 8. 
For identifying metastatic lymph nodes, it has been reported that FDG-PET is superior to 
morphologic imaging because it provides functional data, and thus has better sensitivity and 
specificity than CT 23.  However, technical limitations include relatively poor spatial resolution 
with diminished and/or incorrect anatomical localization, as well as missing small spots of 
increased tracer uptake. Thus, the actual sensitivity of FDG-PET for lymph node metastasis of 
pancreatic cancer has been reported to be between 46% and 71%, with a specificity ranging 
between 63% and 100% 24-28.  Although it is true that patients with obviously unresectable disease 
were not included in our study, so the true sensitivity and specificity of FDG-PET would be 
expected to be higher than shown by our results, FDG-PET data would not change the clinical 
management of the vast majority of patients previously evaluated by CT. 
To obtain more accurate and simpler methods for the diagnosis of PALN metastasis, further 
development of diagnostic modalities will be necessary.  Diffusion-weighted MRI (DWI), MRI 
using lymphotropic contrast agents, and combined PET-CT imaging seem to be the most promising 
modalities currently available for accurate lymph node evaluation 24, 29.  Although further 
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technical advances are necessary to improve spatial resolution and to reduce susceptibility and 
motion artifacts, it is expected that it may become possible to characterize even small lymph nodes 
as benign or malignant in the future 30. 
For example, dextran-coated ultra-small superparamagnetic iron oxide particles (USPIOs) have 
previously been evaluated for specifically enhancing lymphatic tissues and for discriminating 
between malignant and benign lymph nodes 24.  Recently, lymphotrophic nanoparticle-enhanced 
MRI (LNMRI) has emerged has a promising imaging tool for lymph nodes, and it has been reported 
that LNMRI has a significantly higher sensitivity and negative predictive value than CT 31, 32. 
Moreover, other new MRI contrast agents, such as T1-enhancing contrast agents and targeted 
MR contrast agents have been also evaluated for lymph node imaging 24.  Combined PET-CT 
employs the functional physiological information obtained by FDG-PET and the detailed 
anatomical information provided by CT to localize diseased lymph nodes more specifically than can 
be done with a single imaging modality 23, 24; however, differentiating inflammation from 
malignancy and detecting microscopic metastases must still be considered as limitations of PET-CT 
33. 
In conclusion, preoperative detection of PALN metastasis is difficult in patients who are 
considered to be candidates for resection of pancreatic cancer and intraoperative histology is 
absolutely necessary.  It seems that discrimination between benign and malignant lymph nodes by 
current imaging modalities is almost impossible, and further development of imaging methods that 
include functional and qualitative assessment may be necessary.  Until then, intraoperative frozen 
section examination of PALN is recommended before other surgical procedures are performed in 
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Figure 1. Preoperative imaging studies.   
Computed tomography (A and B) and magnetic resonance imaging (C) show an ovoid 13-mm 
para-aortic lymph node (arrows).  18F-fluorodeoxyglucose uptake by a para-aortic lymph node 





Table 1.   
Clinical, surgical, and histopathological findings of 119 patients 
Age (years, mean ± SD [range])   65.0 ± 9.3 [32-85] 
Gender Male 58 (48.7%) 
 Female 61 (51.3%) 
Location Head 79 (66.4%) 
 Body 23 (19.3%) 
 Tail 5 (4.2%) 
 Head + body 1 (0.8%) 
 Body + tail 10 (8,4%) 
 Head + body + tail 1 (0.8%) 
Tumor size (mm, mean ± SD [range]) 31.3 ± 15.6 [8-120] 
Surgery PD, PPPD 54 (45.4%) 
 DP 23 (19.3%) 
 TP 8 (6.7%) 
 Palliation 17 (14.3%) 
 Probe laparotomy 17 (14.3%) 
PALN dissection  71 (60.0%) 
PV or SMV resection   26 (21.8%) 
 
PD, pancreaticoduodenectomy; PPPD, pylorus-preserving pancreaticoduodenectomy; DP, distal 
pancreatectomy; TP, total pancreatectomy; PALN, para-aortic lymph node; PV, portal vein; SMV, 




Table 2.   
Staging of 119 patients by JPS and UICC classification 
 
JPA Stage I 1 (0.8%) 
 II 2 (1.7%) 
 III 21 (17.6%) 
 IV a 59 (50.0%) 
 IV b 36 (30.3%) 
UICC Stage Ia 1 (0.8%) 
 Ib 2 (1.7%) 
 IIa 36 (30.3%) 
 IIb 44 (37.0%) 
 III 4 (3.4%) 
  IV 32 (26.9%) 
 
JPS, Japan Pancreas Society; UICC, Union International Contra la Cancrum 
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Table 3.  
Comparison of clinical characteristics and tumor staging between patients with and without 
para-aortic lymph node metastasis. 
    PALN metastasis (+)  (n=6) 
PALN metastasis 
(-)  (n=65) P value 
Age  65.5 ± 6.2 63.5 ± 10.1 0.63 
Gender Male 3 (50%) 30 (46.2%) 0.83 
 Female 3 (50%) 35 (53.8%)  
Location Head 5 (83.3%) 47 (72.3%) 0.79 
 Body 1 (16.7%) 9 (13.8%)  
 Tail 0 1 (1.5%)  
 Head / body 0 1 (1.5%)  
 Body / tail 0 7 (10.8%)  
Tumor size (mm)  24.4 ± 3.9 30.2 ± 14.0 0.31 
JPS Stage I 0 1 (1.5%) < 0.001 
 II 0 2 (3.1%)  
 III 0 15 (23.1%)  
 IV a 0 42 (64.6%)  
 IV b 6 (100%) 11 (16.9%)  
UICC Stage Ia 0 1 (1.5%) < 0.001 
 Ib 0 2 (3.1%)  
 IIa 0 23 (35.4%)  
 IIb 0 35 (53.8%)  
 III 0 1 (1.5%)  
  IV 6 (100%) 3 (4.6%)  
 
Age and tumor size are expressed as the mean ± SD. 

















CT 69 13 0 79.4% 72.5% 
MRI 69 2 0 96.8% 88.4% 
FDG-PET 69 1 0 98.4% 90.0% 
 
CT, computed tomography; MRI, magnetic resonance imaging; PET, positoron emission 
tomography; PALN, para-aortic lymph node. 
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Table 5.   
Comparison of lymph node size parameters. 
  
PALN metastasis 
(+)  (n=6) 
PALN metastasis 
(-)  (n=65) 
P 
value 
Longer diameter (mm) 8.1 ± 1.0 7.4 ± 2.2 0.42 
Shorter diameter (mm) 5.0 ± 1.1 4.6 ± 1.5 0.56 
Long/Short ratio 1.7 ± 0.4 1.7 ± 0.4 0.80 
Calculated volume (mm3) 122 ± 50 99 ± 85 0.54 
 
PALN, para-aortic lymph node 
Data are expressed as the mean ± SD. 
 
 
